Valeant investigated over Philidor links

12 August 2016

Beleaguered Canadian drugmaker Valeant (TSX: VRX) is being investigated over claims that it conned insurers by hiding its ties to the mail-order pharmacy Philidor Rx Services to boost drug sales.

The company has faced high-profile probes over its large drug price increases in the last year and – until news of this latest investigation broke this week – its recovery under new boss Joe Papa appeared to be underway.

Its share price had soared by more than 25% on the publication of Valeant’s latest quarterly results which reaffirmed 2016 revenue estimates, but the share's value dropped again by more than 10% on Thursday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK